share_log

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K:重大事件
SEC announcement ·  03/15 07:20
Moomoo AI 已提取核心信息
Avenue Therapeutics, Inc. reported on March 11, 2024, that it has received an extension from the Nasdaq Hearings Panel to regain compliance with Nasdaq's minimum stockholders' equity and bid price requirements by May 20, 2024. The company had previously been notified of non-compliance with the stockholders' equity requirement in May 2023 and the bid price requirement in September 2023. Despite submitting a compliance plan, Avenue Therapeutics was unable to meet the stockholders' equity requirement by the initial deadline, leading to a formal notice of potential delisting in November 2023. The company requested a hearing, which took place on February 15, 2024, and resulted in the granted extension. Avenue Therapeutics must now demonstrate a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days by the new deadline. The company is exploring all available options to regain compliance, but there is no assurance of success. The report also contains forward-looking statements regarding the company's plans and potential risks and uncertainties that may affect its financial condition and business prospects.
Avenue Therapeutics, Inc. reported on March 11, 2024, that it has received an extension from the Nasdaq Hearings Panel to regain compliance with Nasdaq's minimum stockholders' equity and bid price requirements by May 20, 2024. The company had previously been notified of non-compliance with the stockholders' equity requirement in May 2023 and the bid price requirement in September 2023. Despite submitting a compliance plan, Avenue Therapeutics was unable to meet the stockholders' equity requirement by the initial deadline, leading to a formal notice of potential delisting in November 2023. The company requested a hearing, which took place on February 15, 2024, and resulted in the granted extension. Avenue Therapeutics must now demonstrate a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days by the new deadline. The company is exploring all available options to regain compliance, but there is no assurance of success. The report also contains forward-looking statements regarding the company's plans and potential risks and uncertainties that may affect its financial condition and business prospects.
Avenue Therapeutics, Inc.于2024年3月11日报告称,它已获得纳斯达克听证会小组的延期,要求在2024年5月20日之前恢复遵守纳斯达克的最低股东权益和出价要求。该公司此前曾在 2023 年 5 月收到不遵守股东权益要求的通知,并在 2023 年 9 月收到投标价格要求的通知。尽管提交了合规计划,但Avenue Therapeutics仍无法在最初的最后期限之前满足股东权益要求,因此在2023年11月发布了可能退市的正式通知。该公司要求举行听证会,该听证会于2024年2月15日举行,并获得了延期。在新的截止日期之前,Avenue Therapeutics现在必须至少连续10个工作日的收盘出价为每股至少1.00美元。该公司正在探索所有可用的选择以恢复合规性,但无法保证成功。该报告还包含有关公司计划以及可能影响其财务状况和业务前景的潜在风险和不确定性的前瞻性陈述。
Avenue Therapeutics, Inc.于2024年3月11日报告称,它已获得纳斯达克听证会小组的延期,要求在2024年5月20日之前恢复遵守纳斯达克的最低股东权益和出价要求。该公司此前曾在 2023 年 5 月收到不遵守股东权益要求的通知,并在 2023 年 9 月收到投标价格要求的通知。尽管提交了合规计划,但Avenue Therapeutics仍无法在最初的最后期限之前满足股东权益要求,因此在2023年11月发布了可能退市的正式通知。该公司要求举行听证会,该听证会于2024年2月15日举行,并获得了延期。在新的截止日期之前,Avenue Therapeutics现在必须至少连续10个工作日的收盘出价为每股至少1.00美元。该公司正在探索所有可用的选择以恢复合规性,但无法保证成功。该报告还包含有关公司计划以及可能影响其财务状况和业务前景的潜在风险和不确定性的前瞻性陈述。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息